• Fludarabine as a DNA Synthesis Inhibitor: Best Practices in

  2026-04-24

  Fludarabine’s precise inhibition of DNA synthesis and apoptosis induction make it indispensable in leukemia and multiple myeloma research. This article details optimized experimental workflows, troubleshooting strategies, and practical applications, leveraging both recent mechanistic insights and the latest immuno-oncology breakthroughs.

• Vorinostat for Epigenetic Modulation in Oncology Workflows

  2026-04-23

  Vorinostat (suberoylanilide hydroxamic acid) empowers cancer biology research by enabling precision epigenetic modulation and apoptosis induction. Discover how optimized use-cases, stepwise protocols, and troubleshooting strategies with this potent HDAC inhibitor can elevate experimental rigor across in vitro oncology models.

• Oridonin Inhibits Bone Loss via MAPK/NF-κB and BMP-2/RUNX2 P

  2026-04-23

  This study demonstrates that oridonin counteracts thioacetamide (TAA)-induced bone loss by suppressing osteoclastogenesis through MAPK/NF-κB signaling and promoting osteoblast differentiation via BMP-2/RUNX2. These findings highlight a dual-action mechanism, offering new insights for inflammation and bone disease research.

• Nonivamide: Applied Workflows for TRPV1 Modulation in Cancer

  2026-04-22

  Nonivamide, a capsaicin analog, enables advanced manipulation of TRPV1-mediated pathways for cancer and neuroimmune research. This article details experimental workflows, troubleshooting insights, and the unique translational advantages of Nonivamide, with actionable guidance for optimizing proliferation and inflammation assays.

• HyperFluor 488 Goat Anti-Mouse IgG: Decoding Synaptic Memory

  2026-04-22

  Explore how the HyperFluor 488 Goat Anti-Mouse IgG antibody advances neuroepigenetic research by enabling precise, high-sensitivity detection in memory-related assays. This article uniquely connects m6A-mediated protein synthesis findings to immunofluorescence design for synaptic plasticity studies.

• Co-Targeting BRD4 and RAC1 Disrupts Tumorigenic Networks in

  2026-04-21

  This study demonstrates that combined inhibition of BRD4 and RAC1 suppresses growth and stemness in diverse breast cancer subtypes by disrupting the c-MYC–G9a–FTH1 axis and downregulating HDAC1. The findings highlight the therapeutic potential of co-targeting epigenetic and signaling pathways to overcome tumor heterogeneity and resistance.

• Zosuquidar (LY335979) 3HCl: Selective P-gp Inhibition in MDR

  2026-04-21

  Zosuquidar (LY335979) 3HCl is a potent, selective P-glycoprotein (P-gp) inhibitor that reverses multidrug resistance (MDR) in cancer models. At 0.1 μM, it fully restores sensitivity to key chemotherapeutics in P-gp-overexpressing leukemia and solid tumor cells. Clinical trials show effective P-gp modulation with minimal added toxicity, making Zosuquidar a benchmark tool for MDR research.

• UBE2F-SAG Mediated RHEB Neddylation Drives mTORC1 in Liver C

  2026-04-20

  This study identifies RHEB as a direct neddylation substrate of the UBE2F-SAG enzymatic axis, revealing a novel regulatory mechanism for mTORC1 activation in liver tumorigenesis. These findings present the UBE2F-SAG-RHEB pathway as a potential target for hepatocellular carcinoma and metabolic liver disease intervention.

• Metronidazole: Applied OAT3 Inhibition & Microbiota Modulati

  2026-04-20

  Metronidazole (2-(2-methyl-5-nitroimidazol-1-yl)ethanol) from APExBIO is a dual-function tool for research on organic anion transporter inhibition and microbiota-immune interactions. This guide delivers actionable workflows, advanced use-cases, and troubleshooting strategies to maximize the impact of Metronidazole in gut-immune and drug-drug interaction studies.

• DMXAA (Vadimezan): Optimizing Tumor Vasculature Disruption A

  2026-04-19

  DMXAA (Vadimezan) empowers researchers to dissect tumor vasculature disruption and apoptosis induction in oncology models, thanks to its dual DT-diaphorase and VEGFR2 inhibition. This guide delivers actionable protocols, troubleshooting strategies, and translational insights rooted in cutting-edge research, ensuring robust, reproducible results.

• Pharmacokinetic Variability of CSBTA in MASH: Mechanistic In

  2026-04-18

  This study investigates how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of major Corydalis saxicola Bunting total alkaloids in mice. The findings reveal that disease status, dosing regimen, and transporter/enzyme modulation collectively influence systemic exposure and hepatic accumulation, providing a framework for optimizing therapeutic strategies in MASLD/MASH.

• Technical Guide: DiI (DiIC18(3)) Plasma Membrane Orange Fluo

  2026-04-17

  DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe addresses the challenge of high-contrast, specific plasma membrane labeling for neuronal tracing, cell migration, and membrane dynamics assays. It is not suitable for water-based applications or for labeling organelles beyond the plasma membrane, and careful protocol adherence is required for reproducible results.

• Integrated Workflow for mRNA Lipid Nanoparticle Formulation

  2026-04-16

  Ma et al. present a comprehensive, stepwise protocol for the formulation, characterization, and evaluation of mRNA lipid nanoparticles (LNPs), addressing a critical need for standardized workflows in mRNA delivery research. By uniting formulation, analytical characterization, and in vitro/in vivo evaluation within a single protocol, the study lowers technical barriers and supports reproducible development of mRNA-based therapeutics.

• Chlorambucil: Applied Workflows for DNA Crosslinking Assays

  2026-04-15

  Chlorambucil, a nitrogen mustard alkylating agent, offers unique advantages for in vitro DNA damage, apoptosis, and cytotoxicity workflows. This article translates current evidence and reference innovations into actionable protocols and troubleshooting for cancer research, maximizing assay reproducibility and data depth.

• YAP-TEAD Orchestrates Super-Enhancer Networks in Surface Ect

  2026-04-14

  This study delineates how the YAP-TEAD transcriptional complex regulates super-enhancer (SE) architecture to control early commitment of surface ectoderm from pluripotent stem cells. By integrating 3D genome mapping and targeted CRISPR perturbations, the work uncovers SE-driven transcriptional networks essential for epithelial lineage specification, offering mechanistic insights relevant for stem cell-based regenerative approaches.

459 records 21/31 page Previous Next First page 上5页 2122232425 下5页 Last page